ScholarLens Back to search
2017•Annals of OncologyOpen access

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

Alessia D’ Alonzo, Claudia Bighin, Fabio Puglisi, Lorenzo Gerratana, Michelino De Laurentis, Andrea Fontana, Palma Pugliese, Antonella Ferzi, Filippo Montemurro, Grazia Arpino, Francesca Benedetta Poggio, Marina Vaglica, Chiara Dellepiane, Eva Blondeaux, C. Benedetta, Francesco Cognetti, Ornella Garrone, Anna Turletti, Sabrina Pastorino, Lucia Del Mastro

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Human Epidermal Growth Factor Receptor 2, Metastatic breast cancer, Oncology, HER2 negative, Internal medicine, Hormone receptor, Breast cancer

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study — Research Paper | ScholarLens